Revance Therapeutics Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 28, 2024 4:30 PM ET
Company Participants
Jessica Serra - Head of Investor Relations & ESG
Mark Foley - CEO & Director
Tobin Schilke - CFO & Principal Accounting Officer
Conference Call Participants
David Amsellem - Piper Sandler
Stacy Ku - TD Cowen
Karishma Raghuram - Goldman Sachs
Jack Padovano - Stifel
Alana Lelo - Guggenheim
John Boyle - William Blair
Terence Flynn - Morgan Stanley
Navann Ty - BNP Paribas
Serge Belanger - Needham & Company
Charles Wang - Mizuho
Operator
Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded on Wednesday, February 28, 2024.
I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Corporate Communications and ESG for Revance. Please go ahead.
Jessica Serra
Thank you, operator. Joining us on the call today from Revance are: Chief Executive Officer, Mark Foley; and Chief Financial Officer, Toby Schilke.
During this call, management will make forward-looking statements, including statements related to the impact of our pricing and strategy on DAXXIFY on adoption, expectations and timing related to product adoption and reorders, our product pipeline, consumer needs, preferences and behavior, the benefits and value to us, practices and consumers of our products, including the efficacy, duration and safety of our products, 2024 guidance, cash flow at even, positive adjusted EBITDA, future capital expenditures, funding our business and capital allocation plans. Our strategic priorities, our anticipated success are blockbuster growth potential, our market opportunity and expectations, provider partnerships, the wind down of OPUL, our strategy, plant operations, international expansion, strategic partnerships and commercialization plans and timing.
Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause these results to be different from these statements, include factors the company describes in the section called Risk Factors in our annual report on Form 10-K to be filed with the SEC today, February 28, 2024. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in our earnings release.